Medical Devices Seed Investors & VC Firms

1155 firms in this list, with a median first check of $500K. 233 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
FI Finchley Healthcare Ventures DGMGPBCC11 people	88🔒	Montreal	CA	Seed–Late Stage	—	+ Add to CRM
I& i&i Biotech Fund IVKKTMAV8 people	88🔒	Prague	CZ	Pre-Seed–Series B	$150K – $2M	+ Add to CRM
NI Nirvana Healthcare Ventures JBFARRGP8 people	88🔒	Cleveland	US	Seed–Series A	$2M – $4M	+ Add to CRM
PA Panakes Partners ABDSFLBC11 people · Follows rounds	88🔒	Milan	IT	Seed–Late Stage	—	+ Add to CRM
SI Sirius Venture Partners GmbH FVMBASJS8 people	88🔒	Wiesbaden	DE	Seed–Growth	$540K – $5.4M	+ Add to CRM
SY Syridex Bio SSVPJACW11 people	88🔒	Princeton	US	Pre-Seed–Late Stage	—	+ Add to CRM
TE tecnet equity NÖ Technologiebeteiligungs-Invest GmbH DACLJMRD8 people	88🔒	St. Pölten	AT	Seed–Series A	$324K – $3.2M	+ Add to CRM
YZ YZR Capital MFRMHEMS11 people	88🔒	Munich	DE	Pre-Seed–Growth	—	+ Add to CRM
NO Noetic SSWW2 people	88🔒	Toronto, Ontario	CA	Seed–Series A	—	+ Add to CRM
BR British Design Fund	88🔒	London	GB	Pre-Seed–Seed	—	+ Add to CRM
IN iNetworks ALAJMDGM9 people	88🔒	Pittsburgh	US	Seed–Late Stage	—	+ Add to CRM
KI KIC Ventures KRAHVLAW9 people	88🔒	Fort Lauderdale	US	Seed–Late Stage	—	+ Add to CRM
MI Militia Hill Ventures JHJLBDS9 people	88🔒	Philadelphia	US	Seed–Series A	—	+ Add to CRM
PA Pathway Bioventures DJMMJSDH5 people	88🔒	Chicago	US	Pre-Seed–Series A	—	+ Add to CRM
SC Scientific Health Development AOPRSFMS5 people	88🔒	Dallas	US	Pre-Seed–Series A	$2M	+ Add to CRM
ZÜ Zühlke Ventures PGSW2 people · Follows rounds	88🔒	Zurich	CH	Pre-Seed–Series A	$165K – $275K	+ Add to CRM
OP OphthaFund GMTMAMJT7 people · Leads rounds	88🔒	Charleston	US	Pre-Seed–Series A	—	+ Add to CRM
TH Thursday Ventures JFMSRMCK4 people · Follows rounds	88🔒	San Francisco	US	Seed–Series C	—	+ Add to CRM
IN Intelligence Ventures DNLLJBMY6 people	88🔒	—		Pre-Seed–Seed	$50K	+ Add to CRM
LI Linden Capital	88🔒	Chicago	DE	Pre-Seed–Series A	—	+ Add to CRM
RO Roche Venture Fund AHDESGCN6 people	88🔒	Basel	CH	Seed–Growth	$648K – $3.2M	+ Add to CRM
AZ AZ Venture Capital Inc. JGSRJPJN5 people · Follows rounds	88🔒	Phoenix	US	Pre-Seed–Series B	—	+ Add to CRM
CL Clal Biotechnology Industries AALNAFBG8 people	88🔒	Tel Aviv	IL	Seed–Late Stage	—	+ Add to CRM
DE DEFTA Partners GHEBKWMI8 people	88🔒	San Francisco	US	Seed–Series A	—	+ Add to CRM

Finchley Healthcare Ventures

MontrealSeed–Late Stage

DGMGPBCC11 people

i&i Biotech Fund

PraguePre-Seed–Series B$150K – $2M

IVKKTMAV8 people

Nirvana Healthcare Ventures

ClevelandSeed–Series A$2M – $4M

JBFARRGP8 people

Panakes Partners

MilanSeed–Late Stage

ABDSFLBC11 people

Sirius Venture Partners GmbH

WiesbadenSeed–Growth$540K – $5.4M

FVMBASJS8 people

Syridex Bio

PrincetonPre-Seed–Late Stage

SSVPJACW11 people

tecnet equity NÖ Technologiebeteiligungs-Invest GmbH

St. PöltenSeed–Series A$324K – $3.2M

DACLJMRD8 people

YZR Capital

MunichPre-Seed–Growth

MFRMHEMS11 people

Noetic

Toronto, OntarioSeed–Series A

SSWW2 people

British Design Fund

LondonPre-Seed–Seed

iNetworks

PittsburghSeed–Late Stage

ALAJMDGM9 people

KIC Ventures

Fort LauderdaleSeed–Late Stage

KRAHVLAW9 people

Militia Hill Ventures

PhiladelphiaSeed–Series A

JHJLBDS9 people

Pathway Bioventures

ChicagoPre-Seed–Series A

DJMMJSDH5 people

Scientific Health Development

DallasPre-Seed–Series A$2M

AOPRSFMS5 people

Zühlke Ventures

ZurichPre-Seed–Series A$165K – $275K

PGSW2 people

OphthaFund

CharlestonPre-Seed–Series A

GMTMAMJT7 people

Thursday Ventures

San FranciscoSeed–Series C

JFMSRMCK4 people

Intelligence Ventures

Pre-Seed–Seed$50K

DNLLJBMY6 people

Linden Capital

ChicagoPre-Seed–Series A

Roche Venture Fund

BaselSeed–Growth$648K – $3.2M

AHDESGCN6 people

AZ Venture Capital Inc.

PhoenixPre-Seed–Series B

JGSRJPJN5 people

Clal Biotechnology Industries

Tel AvivSeed–Late Stage

AALNAFBG8 people

DEFTA Partners

San FranciscoSeed–Series A

GHEBKWMI8 people

Data sourced from public filings and firms' own websites — see our methodology.